|
Nov 8
|
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics
|
|
Nov 7
|
Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates
|
|
Nov 7
|
UPDATE 1-Gilead quarterly results beat Street estimates as lower taxes boost profit
|
|
Nov 7
|
Gilead quarterly results beat Street estimates as lower taxes boost profit
|
|
Nov 7
|
Gilead Sciences Announces Third Quarter 2023 Financial Results
|
|
Nov 7
|
Gilead quarterly results beat Street estimates as profit up on lower taxes
|
|
Nov 7
|
Gilead Sciences: Advancing Global Health Equity in Tropical Regions
|
|
Nov 6
|
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers
|
|
Nov 6
|
Institutional investors must be pleased after a 4.9% gain last week that adds to Gilead Sciences, Inc.'s (NASDAQ:GILD) one-year returns
|
|
Nov 3
|
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
|
|
Nov 2
|
Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline
|
|
Nov 2
|
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
|
|
Nov 1
|
Is Now The Time To Put Gilead Sciences (NASDAQ:GILD) On Your Watchlist?
|
|
Oct 31
|
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
|
|
Oct 31
|
Gilead's Commitment to Advancing Health Equity for Black Women and Ending the HIV Epidemic
|
|
Oct 31
|
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
|
|
Oct 26
|
3 Pharma Stocks That Are Screaming Buys in October
|
|
Oct 25
|
Should We Be Delighted With Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Of 26%?
|
|
Oct 25
|
USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day
|